|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group, and hypertension occurred at a higher frequency in the epoetin alfa group.
|
31340116 |
2019 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
We investigated the protective effect of erythropoietin against tissue damage caused by hypertension in the kidney and whether this effect was suppressed by TNF-α.
|
29843153 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Drugs used commonly as adjuvants such as steroids, erythropoietin stimulating agents etc, may also cause rise in blood pressure or exacerbate preexisiting hypertension.
|
29755695 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The databases were searched for articles (Science Direct, Pub Med and Web of Science) and patents (INPI, WIPO and EPO) with publications on R. officinalis and associations with essential oil (EO-Ro), cardiovascular system, hypertension and cyclodextrin.
|
29633892 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Nevertheless, tissue protective effect of EPO could not be translated to the clinical trials because of common lethal thromboembolic events, erythropoiesis and hypertension.
|
29680240 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
There is little evidence for EPO as a direct vasoconstrictor or its effect on blood viscosity as a mechanism of EPO-induced hypertension.
|
29228345 |
2018 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Three studies assessed the effects of differing frequencies of CERA administration and five assessed differing CERA doses.There was low certainty evidence that CERA had little or no effects on mortality (RR 1.07, 95% CI 0.73 to 1.57; RR 1.11, 95% CI 0.75 to 1.65), major adverse cardiovascular events (RR 5.09, 95% CI 0.25 to 105.23; RR 5.56, 95% CI 0.99 to 31.30), hypertension (RR 1.01, 95% CI 0.75 to 1.37; RR 1.00, 95% CI 0.79 to 1.28), need for blood transfusion (RR 1.02, 95% CI 0.72 to 1.46; RR 0.94, 95% CI 0.55 to 1.61), or additional iron therapy (RR 1.03, 95% CI 0.91 to 1.15; RR 0.99, 95% CI 0.95 to 1.03) compared to epoetin alfa/beta or darbepoetin alfa respectively.
|
28782299 |
2017 |
|
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnea and the use of erythropoietin-stimulating agents may also be involved.
|
28157814 |
2017 |
|
Hypertensive disease
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnoea and the use of erythropoietin-stimulating agents may also be involved.
|
28340239 |
2017 |
|
Hypertensive disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we describe an infant of Bangladesh ethnicity with a novel homozygous VHL(D126N) mutation with congenital polycythemia and dramatically elevated erythropoietin (EPO) levels, who developed severe fatal pulmonary hypertension.
|
24729484 |
2014 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
However, treatment can result in rhEPO levels greatly exceeding the normal physiological range for endogenous EPO, and there is evidence that this contributes to hypertension in patients with CKD.
|
25392999 |
2014 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Previously detected single nucleotide polymorphisms in the hypoxia-responsive element of EPO might be associated with hypertension and hypertensive end organ damages.
|
21912181 |
2012 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The underlying mechanisms of EPO-induced hypertension still remain to be determined.
|
21690481 |
2011 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients.
|
19458615 |
2009 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
A panel of 42 transcripts differentiated patients with RVA and HTN from three sets of matched controls, with and without HTN and EPO use, with 100% concordance (p < 0.001).
|
17845633 |
2007 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
We have recently demonstrated that endogenous erythropoietin (Epo)/Epo receptor (EpoR) system plays an important protective role in hypoxia-induced pulmonary hypertension.
|
17293480 |
2007 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Our preliminary research indicates that individuals who carry two copies of the T allele, i.e., who are homozygous for T, are highly susceptible to development of hypertension when subjected to Epo.
|
11675943 |
2001 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
CTD_human |
These results point to a possible role for EPO as the mediator of cortisol-induced hypertension.
|
10694834 |
2000 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
BEFREE |
It appears that hemodialysis patients with a positive family history of hypertension are susceptible to developing hypertension during treatment with rHuEPO.
|
8475933 |
1993 |
|
Hypertensive disease
|
0.400 |
Biomarker
|
group |
CTD_human |
It is not known whether recombinant human erythropoietin has a direct, clinically apparent pressor effect in hemodialysis patients or whether hypertension developing or aggravated in these patients merely reflects increased hematocrit.
|
1516988 |
1992 |